3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
7
Ovarian Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms, Unknown Primary
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Interventions
Oxaliplatin
10
Capecitabine
9
Cisplatin
8
Fluorouracil
5
Leucovorin
4
Bevacizumab
4
tegafur-gimeracil-oteracil
3
pemigatinib
3
atezolizumab
3
Nivolumab
3
trebananib
2
ponatinib
2
pembrolizumab
2
avelumab
2
apatinib
2
alectinib
2
XELOX
2
Standard of Care
2
S 1 (combination)
2
Radiotherapy
2
Radiosurgery
2
Ocoxin
2
Irinotecan
2
Ipilimumab
2
Gemcitabine
2
Folfox protocol
2
Everolimus
2
Erlotinib Hydrochloride
2
Acupuncture Therapy
2
zanidatamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gastrointestinal Neoplasms
×
ipatasertib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled